XENON PHARMACEUTICALS INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
XENON PHARMACEUTICALS INC. (XENE) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $23.08 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- XENON PHARMACEUTICALS INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2020 was 7.60 CAD/shares, a 36.69% increase from fiscal 2019.
- XENON PHARMACEUTICALS INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2019 was 5.56 CAD/shares, a 21.66% increase from fiscal 2018.
- XENON PHARMACEUTICALS INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2018 was 4.57 CAD/shares, a 22.85% increase from fiscal 2017.
- XENON PHARMACEUTICALS INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2017 was 3.72 CAD/shares, a 1.36% increase from fiscal 2016.
CAD/shares
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2020-12-31 | 7.60 CAD/shares 10-K · filed 2021-03-01 |
| 2019-12-31 | 5.56 CAD/shares 10-K · filed 2021-03-01 |
| 2018-12-31 | 4.57 CAD/shares 10-K · filed 2020-03-09 |
| 2017-12-31 | 3.72 CAD/shares 10-K · filed 2019-03-06 |
| 2016-12-31 | 3.67 CAD/shares 10-K · filed 2018-03-07 |
| 2015-12-31 | 4.66 CAD/shares 10-K · filed 2018-03-07 |
| 2014-12-31 | 6.07 CAD/shares 10-K · filed 2017-03-08 |
| 2013-12-31 | 6.07 CAD/shares 10-K · filed 2016-03-08 |
USD/shares
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $23.08 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $21.87 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $20.56 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $17.71 10-Q · filed 2025-11-03 | |||
| 2025-06-30 | $17.01 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $17.31 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $12.43 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $13.81 10-Q · filed 2025-11-03 | |||
| 2024-06-30 | $14.51 10-Q · filed 2025-08-11 | |||
| 2024-03-31 | $23.42 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $13.58 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $11.21 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | $11.15 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $6.49 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $9.47 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $7.34 10-K · filed 2024-02-29 | |||
| 2020-12-31 | $5.76 10-K · filed 2023-03-01 | |||
| 2019-12-31 | $4.24 10-K · filed 2021-03-01 | |||
| 2018-12-31 | $3.53 10-K · filed 2020-03-09 | |||
| 2017-12-31 | $2.86 10-K · filed 2019-03-06 | |||
| 2016-12-31 | $2.77 10-K · filed 2018-03-07 | |||
| 2015-12-31 | $3.65 10-K · filed 2018-03-07 | |||
| 2014-12-31 | $5.23 10-K · filed 2017-03-08 | |||
| 2013-12-31 | $5.88 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |